Prelude Therapeutics, Inc. (PRLD)
3.89
+0.01
(+0.26%)
USD |
NASDAQ |
Oct 09, 16:00
3.96
+0.07
(+1.80%)
After-Hours: 20:00
Prelude Therapeutics Cash from Operations (Quarterly) : -15.57M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.57M |
| March 31, 2026 | -21.68M |
| December 31, 2025 | 23.12M |
| September 30, 2025 | -19.12M |
| June 30, 2025 | -26.08M |
| March 31, 2025 | -34.23M |
| December 31, 2024 | -20.74M |
| September 30, 2024 | -27.30M |
| June 30, 2024 | -23.06M |
| March 31, 2024 | -31.79M |
| December 31, 2023 | -23.58M |
| September 30, 2023 | -25.68M |
| June 30, 2023 | -27.67M |
| March 31, 2023 | -30.13M |
| Date | Value |
|---|---|
| December 31, 2022 | -22.93M |
| September 30, 2022 | -20.44M |
| June 30, 2022 | -18.47M |
| March 31, 2022 | -21.90M |
| December 31, 2021 | -25.70M |
| September 30, 2021 | -21.77M |
| June 30, 2021 | -19.91M |
| March 31, 2021 | -16.14M |
| December 31, 2020 | -14.85M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -9.921M |
| December 31, 2019 | -8.469M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Q32 Bio, Inc. | -3.075M |
| Intellia Therapeutics, Inc. | -83.11M |
| Twist Bioscience Corp. | 1.115M |
| Beam Therapeutics, Inc. | -66.10M |
| Revolution Medicines, Inc. | -387.32M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -65.50M |
| Cash from Financing (Quarterly) | 85.82M |
| Free Cash Flow | -33.26M |
| Free Cash Flow Per Share (Quarterly) | -0.1583 |
| Free Cash Flow to Equity (Quarterly) | -15.50M |
| Free Cash Flow to Firm (Quarterly) | -15.57M |
| Free Cash Flow Yield | -10.69% |